In 2025, Medgen Life Science achieved major breakthroughs in product innovation, international expansion, and industry standard-setting, delivering a year of high-quality growth.
Medgen's PoroGraft® oral bone filling material receives Class D medical device registration in Vietnam — the highest risk classification — becoming the company's third product approved in Vietnam and marking the systematic deployment of a multi-product portfolio in Southeast Asia.
Medgen Life Science has been named a "Quality, Safe, and Trusted Medical Aesthetics Service Provider" for the fourth consecutive year, delivering regenerative material solutions built to medical-grade standards.
Following its Vietnam Class C registration, Medgen's PRP preparation device secures Indonesia Class B medical device registration, adding another key market to the company's global expansion strategy.
First installment of the BoneSwift™ injectable bone graft material clinical case series for spinal bone defect repair, showcasing clinical applications in spinal surgery.
Medgen's independently developed Platelet-Rich Plasma (PRP) preparation device receives Class C medical device registration in Vietnam, following its NMPA Class III approval in China, marking a key step in the company's Southeast Asian expansion.
Medgen Life Science has been officially designated as a Shenzhen "Specialized, Refined, Differentiated, and Novel" (SRDN) small and medium enterprise in recognition of its sustained technological innovation.
Platelet-Rich Plasma (PRP) regenerative therapy extracts high-concentration growth factors from the patient's own blood to reduce inflammation, relieve pain, and accelerate tissue regeneration.
PoroGraft® bone graft features a calcium-phosphorus ratio and zinc-magnesium ion content highly similar to human bone, efficiently regulating cell behavior, rapidly adsorbing bioactive substances, promoting cell migration and differentiation, and inducing bone regeneration.
Medgen's independently developed bone graft material has been selected for the Shenzhen Key New Materials First-Batch Application Demonstration Directory, receiving official government recognition.
Second installment of the BoneSwift™ injectable bone graft material clinical case series for limb bone defect repair, highlighting product handling and intraoperative performance.
PoroGraft® oral bone graft features excellent hydrophilicity and clumping properties, with purity exceeding 95% and no post-surgical rejection. Sourced from natural porcine femoral metaphyseal cancellous bone with a calcium-phosphorus ratio similar to human bone.
First installment of the BoneSwift™ injectable bone graft material clinical case series for limb bone defect repair, showcasing real-world clinical applications.
PoroGraft® bone graft is sourced from natural porcine femoral metaphyseal cancellous bone, with only 20-40g extractable per pig. Its intact natural microporous structure, rougher surface area, and higher zinc-magnesium content provide an ideal scaffold for oral bone regeneration.
Medgen's independently developed BoneSwift™ pre-filled injectable bone filling material receives Class D medical device registration from Vietnam's Ministry of Health, the highest risk classification in Vietnam's regulatory system.
PoroGraft® represents a new direction for oral bone grafting in China, featuring premium natural porcine cancellous bone, gradient temperature-rising calcination for high-purity quality, and calcium-phosphorus ratio with zinc-magnesium content similar to human bone for efficient bone regeneration.
The Medgen PRP Preparation Device features a three-chamber integrated design, optimized two-step centrifugation, and three patented safety technologies, achieving 4.3-6.8x platelet concentration with >99% red blood cell removal rate.
After 8 years of independent R&D, Medgen Life Science's three core products — BoneSwift™ injectable bone graft, PoroGraft® oral bone filler, and PRP preparation device — have all received NMPA Class III medical device certification, with multiple technologies filling domestic market gaps.
Medgen Life Science and Shanghai Sanyou Medical Devices (688085.SH) sign a national logistics service agreement for BoneSwift™ bone filling materials, launching a strategic orthopedic market partnership.
Hangzhou Qiantang Longyue Biotech and Medgen Life Science sign a strategic cooperation agreement, combining core strengths in precision medical devices and biomaterials to advance innovative product development and industrialization.
A comparative analysis of porcine and bovine bone graft materials across material source, microstructure, biocompatibility, and osteogenic performance, exploring the scientific advantages of porcine-derived bone repair materials.
Medgen Life Science's independently developed PoroGraft® oral bone graft material has officially launched — the first domestically produced porcine-derived xenograft bone graft in China, offering a new treatment experience for oral restoration.
Medgen Life Science received the "Quality, Safe, and Trusted Medical Aesthetics Service Provider" award for the third consecutive year from the Shenzhen Plastic and Cosmetic Surgery Industry Association.
Medgen Life Science's BoneSwift™ receives NMPA Class III certification as China's first hydroxyapatite pre-filled bone repair material, offering ready-to-use convenience and enhanced surgical efficiency.
Medgen completes its Series A+ round exclusively invested by Yuansheng Venture Capital, bringing total funding across two rounds to nearly RMB 100 million within two months.
Exclusively invested by Huaxi Yuanyou Fund, Medgen Life Science completed its Series A financing to advance its multi-product regenerative repair material platform across orthopedics, aesthetics, and sports medicine.
Two group standards co-drafted by Medgen — covering injectable hydroxyapatite microsphere gel and degradation/collagen regeneration evaluation methods for facial soft tissue implants — have passed project approval review.
PRP has demonstrated excellent results in anti-aging skin care, wrinkle reduction, pigmentation improvement, and facial volume restoration, making it a key treatment modality in facial rejuvenation.
PRP therapy releases multiple growth factors that effectively promote knee cartilage repair and pain relief, offering a new treatment option for patients with knee osteoarthritis.
Medgen's major science and technology project on "Key Technologies for Composite Materials for Artificial Tendons" has received project funding from the Shenzhen Science and Technology Innovation Commission.
Medgen's independently developed BoneSwift™, China's first pre-filled injectable artificial bone, has completed all clinical trial subject follow-ups, with safety and efficacy fully validated.
Medgen Life Science's independently developed first domestic pre-filled injectable bone graft has completed clinical trial follow-ups across three centers, marking a major milestone in the company's bone filling material development and a significant step toward commercialization.
Medgen Life Science was selected among the national top 100 at the "Innovation China" Innovation and Entrepreneurship Investment Conference, showcasing its resorbable artificial bone and regenerative repair materials.
Medgen Life Science won dual awards at the 6th China Medical Device Innovation and Entrepreneurship Competition with its "Inducible Bone Repair Material" and "Rotator Cuff Patch" projects.
Medgen Life Science has been officially certified as a National High-Tech Enterprise by China's Ministry of Science and Technology, recognizing the company's innovation capabilities, R&D strength, and technology commercialization.